FDA has approved Medtronic 's Deep Brain Stimulation (DBS) therapy for patients with Parkinson's disease and help them in movement of their limbs.
The device underwent a clinical study, EARLYSTIM which found that patients treated with Medtronic DBS Therapy and best medical therapy (BMT) reported a mean improvement of 26 percent in their disease-related quality of life at two years.
‘Deep Brian Stimulation Therapy offers Parkinson's patients with recent onset of motor fluctuations and dyskinesias a better quality of life.’
DBS therapy uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver electrical stimulation to precisely targeted areas of the brain.
This stimulation reduces some of the most disabling motor symptoms associated with Parkinson's disease, including shaking, stiffness and movement difficulties.
Medtronic's DBS systems are the first and only approved for full-body MRI scans under specific conditions. In most cases, DBS therapy is reversible and the system can be removed.
"Strong clinical evidence demonstrates that, when compared to the best medical treatment alone, Medtronic DBS Therapy offers Parkinson's patients with recent onset of motor fluctuations and dyskinesias not adequately controlled with medication a higher likelihood of symptom improvement.," said Mahlon DeLong, M.D., the W. P. Timmie professor of neurology at Emory University School of Medicine.